Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 24;58(9):e00410-20.
doi: 10.1128/JCM.00410-20. Print 2020 Aug 24.

Accuracy of Xpert Ultra in Diagnosis of Pulmonary Tuberculosis among Children in Uganda: a Substudy from the SHINE Trial

Affiliations

Accuracy of Xpert Ultra in Diagnosis of Pulmonary Tuberculosis among Children in Uganda: a Substudy from the SHINE Trial

Willy Ssengooba et al. J Clin Microbiol. .

Abstract

Childhood tuberculosis (TB) presents significant diagnostic challenges associated with paucibacillary disease and requires a more sensitive test. We evaluated the diagnostic accuracy of Xpert MTB/RIF Ultra (Ultra) compared to other microbiological tests using respiratory samples from Ugandan children in the SHINE trial. SHINE is a randomized trial evaluating shorter treatment in 1,204 children with minimal TB disease in Africa and India. Among 352 samples and one cervical lymph node fine needle aspirate, one sample was randomly selected per patient and tested with the Xpert MTB/RIF assay (Xpert) and with Lowenstein-Jensen medium (LJ) and liquid mycobacterial growth indicator tube (MGIT) cultures. We selected only uncontaminated stored sample pellets for Ultra testing. We estimated the sensitivity of Xpert and Ultra against culture and a composite microbiological reference standard (any positive result). Of 398 children, 353 (89%) had culture, Xpert, and Ultra results. The median age was 2.8 years (interquartile range [IQR], 1.3 to 5.3); 8.5% (30/353) were HIV infected, and 54.4% (192/353) were male. Of the 353, 31 (9%) were positive by LJ and/or MGIT culture, 36 (10%) by Ultra, and 16 (5%) by Xpert. Sensitivities (95% confidence intervals [CI]) were 58% (39 to 65% [18/31]) for Ultra and 45% (27 to 64% [14/31]) for Xpert against any culture-positive result, with false positives of <1% and 5.5% for Xpert and Ultra. Against a composite microbiological reference, sensitivities were 72% (58 to 84% [36/50]) for Ultra and 32% (20 to 47% [16/50]) for Xpert. However, there were 17 samples that were positive only with Ultra (majority trace). Among children screened for minimal TB in Uganda, Ultra has higher sensitivity than Xpert. This represents an important advance for a condition which has posed a diagnostic challenge for decades.

Keywords: Xpert Ultra; accuracy; childhood; diagnosis; tuberculosis.

PubMed Disclaimer

Figures

FIG 1
FIG 1
STARD (standards for reporting diagnostic accuracy) flowchart of the Ultra substudy. Xpert, Xpert MTB/RIF; Ultra, Xpert MTB/RIF Ultra; LJ, Lowenstein-Jensen medium culture; MGIT, mycobacterial growth indicator tube culture.
FIG 2
FIG 2
Venn diagram showing proportion of patients diagnosed by each test and a combination of tests (n = 353). Xpert, Xpert MTB/RIF; Ultra, Xpert MTB/RIF Ultra; LJ, Lowenstein-Jensen medium culture; MGIT, mycobacterial growth indicator tube culture.

References

    1. Dodd PJ, Yuen CM, Sismanidis C, Seddon JA, Jenkins HE. 2017. The global burden of tuberculosis mortality in children: a mathematical modelling study. Lancet Glob Health 5:e898–e906. doi:10.1016/S2214-109X(17)30289-9. - DOI - PMC - PubMed
    1. Kunkel A, Abel Zur Wiesch P, Nathavitharana RR, Marx FM, Jenkins HE, Cohen T. 2016. Smear positivity in paediatric and adult tuberculosis: systematic review and meta-analysis. BMC Infect Dis 16:282. doi:10.1186/s12879-016-1617-9. - DOI - PMC - PubMed
    1. Marais BJ, Graham SM. 2016. Childhood tuberculosis: a roadmap towards zero deaths. J Paediatr Child Health 52:258–261. doi:10.1111/jpc.12647. - DOI - PubMed
    1. WHO. 2015. The end TB strategy. World Health Organization, Geneva, Switzerland.
    1. Cepheid. 2017. 2017 launch of new TB test Ultra backed by WHO recommendation. Cepheid, Sunnyvale, CA.

Publication types